90914-41-3

Basic information

• Product Name: 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE
• Synonyms: 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE;1H-Pyrazolo[3,4-d]pyriMidine, 3-broMo-4-chloro-;3-broMo-4-chloropyrazolopyriMidine;3-bromo-4-chloro-2H-pyrazolo[3,4-d]pyrimidine
• CAS NO: 90914-41-3
• Molecular Formula: C₅H₂BrClN₄
• Molecular Weight: 233.45
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 90914-41-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 2.128g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.766
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.36±0.20(Predicted)
• CAS DataBase Reference: 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(90914-41-3)
• EPA Substance Registry System: 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(90914-41-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 90914-41-3(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine is a chemical compound with the molecular formula C5H2BrClN4. It is a heterocyclic compound that consists of a pyrazolo[3,4-d]pyrimidine core with bromine and chlorine substituents at the 3 and 4 positions, respectively. 3-BROMO-4-CHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE may have potential applications in the pharmaceutical industry, particularly in the development of new drugs and agrochemicals. It is important to note that this compound should be handled with care, as it may pose health hazards and environmental risks if not properly managed.

InChI:InChI=1/C5H2BrClN4/c6-3-2-4(7)8-1-9-5(2)11-10-3/h1H,(H,8,9,10,11)

Upstream product

• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 1240526-73-1 3-bromo-4-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine 

Relevant articles and documents

Revisiting Pyrazolo[3,4- d]pyrimidine Nucleosides as Anti- Trypanosoma cruzi and Antileishmanial Agents

Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-Trypanosoma brucei and anti-Trypanosoma cruzi activities. In this work, we report the design and synthesis of pyrazolo[3,4-d]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-Trypanosoma cruzi and antileishmanial agents. One compound was selected for in vivo evaluation in an acute Chagas disease mouse model.

Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant

A series of AKT inhibitors possessing a piperidin-4-yl side chain was designed and synthesized. Some of them showed high AKT1 inhibitory activity and potent anti-proliferative effect on PC-3 prostate cancer cells in the preliminary screening. Further studies revealed the most potent compound, 10h, as a pan-AKT inhibitor. Compound 10h was able to inhibit the cellular phosphorylation of AKT effectively and induce apoptosis of PC-3 cells. It also showed high metabolic stability in human liver microsomes. Preclinical characterization of 10h, a promising lead AKT inhibitor, as a potential anti-prostate cancer therapeutic needs to be further investigated.

INHIBITORS OF THE TEC KINASE ENZYME FAMILY

The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.